|
related topics |
{property, intellectual, protect} |
{stock, price, operating} |
{stock, price, share} |
{provision, law, control} |
{interest, director, officer} |
{customer, product, revenue} |
{control, financial, internal} |
|
Our auditors have raised substantial doubt about our ability to continue as a going concern.
Operating losses may continue, which could adversely affect financial results from operations and stockholder value.
We have experienced significant declines in revenues in recent periods which, if continued, could adversely affect stockholder value.
Our competitors could develop products or technologies that could make our products or technologies non-competitive, which would adversely affect sales, financial results from operations and stockholder value.
If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market, our financial results from operations and stockholder value.
A significant portion of our sales are derived from a limited number of customers, and results from operations could be adversely affected and shareholder value harmed if we lost any of these customers.
Risks Related to our Capital Structure
The market price of our stock can be volatile, which could result in losses for investors.
Statutory provisions and provisions in our charter may delay or frustrate transactions that may be beneficial to our stockholders.
Resale by the holder of the Notes and Warrants could adversely affect the market price of our stock.
Full 10-K form ▸
|
|
related documents |
727634--3/30/2006--COMMUNICATION_INTELLIGENCE_CORP |
714256--4/4/2008--MB_SOFTWARE_CORP |
708850--8/29/2007--DIONEX_CORP_/DE |
1103390--2/21/2006--INTRABIOTICS_PHARMACEUTICALS_INC_/DE |
758004--5/25/2007--NOVELL_INC |
911148--3/30/2007--CADUS_CORP |
1102934--11/27/2007--CABOT_MICROELECTRONICS_CORP |
732412--3/31/2008--MULTIBAND_CORP |
946356--3/9/2007--OAKLEY_INC |
911148--3/31/2008--CADUS_CORP |
99302--6/26/2008--TRANSCAT_INC |
1361658--2/29/2008--WYNDHAM_WORLDWIDE_CORP |
99302--6/27/2007--TRANSCAT_INC |
1042173--3/8/2007--SCIENTIFIC_LEARNING_CORP |
1040792--3/29/2006--A_CONSULTING_TEAM_INC |
805305--12/30/2008--QUIKSILVER_INC |
844161--4/17/2008--CHEROKEE_INC |
844161--4/15/2010--CHEROKEE_INC |
911160--5/27/2009--RF_MICRO_DEVICES_INC |
883107--3/14/2007--NANOPHASE_TECHNOLOGIES_CORPORATION |
853695--3/28/2007--DIGITAL_RECORDERS_INC |
1016504--10/14/2008--INTEGRATED_BIOPHARMA_INC |
786623--3/12/2007--ADVANCED_VIRAL_RESEARCH_CORP |
844161--4/13/2009--CHEROKEE_INC |
1029023--3/2/2009--SYNTROLEUM_CORP |
853695--4/15/2010--DRI_CORP |
853695--3/31/2009--DRI_CORP |
1102542--1/29/2009--SCO_GROUP_INC |
1066104--3/1/2007--CORPORATE_EXECUTIVE_BOARD_CO |
1000180--2/28/2007--SANDISK_CORP |
|